AIMS: To investigate the vascular risk associated with Metabolic Syndrome (MetS) according to different clinical criteria with subsequent vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral artery disease or abdominal aortic aneurysm and to examine whether patients with MetS at treatment goals for systolic blood pressure (SBP) or low density lipoprotein-cholesterol (LDL-c) level are still at elevated risk. METHODS AND RESULTS: Prospective study of 3196 patients with a history or recent diagnosis of clinically manifest vascular disease. During a median follow-up of 3.2 years (interquartile range 1.4-5.4 years), 331 patients died and 373 patients experienced a first vascular event. National Cholesterol Education Program (NCEP) and revised NCEP (NCEP-R)-defined MetS were related to increased risk of vascular events [HR - hazard ratio 1.50 (95% CI - confidence interval 1.22-1.84) and 1.50 (1.22-1.87)] and all-cause mortality [HR 1.49(1.20-1.84) and 1.43 (1.14-1.78)]. Results were similar in the 2472 patients without type 2 diabetes (DM2) and localization of vascular disease; SBP-category (<140 or > or =140 mmHg) or LDL-category (<2.5 or > or =2.5 mmol/L) did not affect this relation. CONCLUSION: In patients with various manifestations of atherosclerosis, presence of NCEP and NCEP-R-defined MetS is associated with increased risk of cardiovascular events and all-cause mortality, independently of the presence of DM2. This risk is significantly higher than the risk associated with International Diabetes Federation-defined MetS. Also in patients at treatment goals for SBP (<140 mmHg) or LDL-c (<2.5 mmol/L) according to current guidelines, presence of NCEP-R-defined MetS points to a higher vascular risk.
AIMS: To investigate the vascular risk associated with Metabolic Syndrome (MetS) according to different clinical criteria with subsequent vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral artery disease or abdominal aortic aneurysm and to examine whether patients with MetS at treatment goals for systolic blood pressure (SBP) or low density lipoprotein-cholesterol (LDL-c) level are still at elevated risk. METHODS AND RESULTS: Prospective study of 3196 patients with a history or recent diagnosis of clinically manifest vascular disease. During a median follow-up of 3.2 years (interquartile range 1.4-5.4 years), 331 patients died and 373 patients experienced a first vascular event. National Cholesterol Education Program (NCEP) and revised NCEP (NCEP-R)-defined MetS were related to increased risk of vascular events [HR - hazard ratio 1.50 (95% CI - confidence interval 1.22-1.84) and 1.50 (1.22-1.87)] and all-cause mortality [HR 1.49(1.20-1.84) and 1.43 (1.14-1.78)]. Results were similar in the 2472 patients without type 2 diabetes (DM2) and localization of vascular disease; SBP-category (<140 or > or =140 mmHg) or LDL-category (<2.5 or > or =2.5 mmol/L) did not affect this relation. CONCLUSION: In patients with various manifestations of atherosclerosis, presence of NCEP and NCEP-R-defined MetS is associated with increased risk of cardiovascular events and all-cause mortality, independently of the presence of DM2. This risk is significantly higher than the risk associated with International Diabetes Federation-defined MetS. Also in patients at treatment goals for SBP (<140 mmHg) or LDL-c (<2.5 mmol/L) according to current guidelines, presence of NCEP-R-defined MetS points to a higher vascular risk.
Authors: May A Beydoun; Marie T Fanelli Kuczmarski; Youfa Wang; Marc A Mason; Michele K Evans; Alan B Zonderman Journal: Public Health Nutr Date: 2010-09-21 Impact factor: 4.022
Authors: Janice V Huang; Li Lu; Shuyu Ye; Bryan C Bergman; Genevieve C Sparagna; Mohammad Sarraf; Jane E B Reusch; Clifford R Greyson; Gregory G Schwartz Journal: Am J Physiol Heart Circ Physiol Date: 2013-01-18 Impact factor: 4.733
Authors: Osman Turak; Barış Afşar; Fırat Ozcan; Fatih Öksüz; Mehmet Ali Mendi; Çagrı Yayla; Adrian Covic; Nathan Bertelsen; Mehmet Kanbay Journal: J Clin Hypertens (Greenwich) Date: 2015-12-22 Impact factor: 3.738
Authors: Björn Eliasson; Jan Cederholm; Katarina Eeg-Olofsson; Anne-Marie Svensson; Björn Zethelius; Soffia Gudbjörnsdottir Journal: Diabetes Care Date: 2011-07-20 Impact factor: 19.112
Authors: Katrin Kepp; Elin Org; Siim Sõber; Piret Kelgo; Margus Viigimaa; Gudrun Veldre; Neeme Tõnisson; Peeter Juhanson; Margus Putku; Andreas Kindmark; Viktor Kozich; Maris Laan Journal: BMC Med Genet Date: 2010-01-28 Impact factor: 2.103
Authors: Ahila Ayyavoo; José G B Derraik; Paul L Hofman; Sarah Mathai; Janene Biggs; Peter Stone; Lynn Sadler; Wayne S Cutfield Journal: PLoS One Date: 2013-07-01 Impact factor: 3.240